IL281335B2 - A gabaa receptor ligand - Google Patents
A gabaa receptor ligandInfo
- Publication number
- IL281335B2 IL281335B2 IL281335A IL28133521A IL281335B2 IL 281335 B2 IL281335 B2 IL 281335B2 IL 281335 A IL281335 A IL 281335A IL 28133521 A IL28133521 A IL 28133521A IL 281335 B2 IL281335 B2 IL 281335B2
- Authority
- IL
- Israel
- Prior art keywords
- compound
- pct
- rats
- treatment
- pain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18194297 | 2018-09-13 | ||
| PCT/EP2019/074465 WO2020053377A1 (en) | 2018-09-13 | 2019-09-13 | A gabaa receptor ligand |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL281335A IL281335A (en) | 2021-04-29 |
| IL281335B1 IL281335B1 (en) | 2024-03-01 |
| IL281335B2 true IL281335B2 (en) | 2024-07-01 |
Family
ID=63579205
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL281335A IL281335B2 (en) | 2018-09-13 | 2019-09-13 | A gabaa receptor ligand |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US11396510B2 (enExample) |
| EP (1) | EP3849976B1 (enExample) |
| JP (1) | JP7353663B2 (enExample) |
| KR (1) | KR102712565B1 (enExample) |
| CN (1) | CN112714765B (enExample) |
| AU (1) | AU2019338236B2 (enExample) |
| BR (1) | BR112021004661A2 (enExample) |
| CA (1) | CA3110283A1 (enExample) |
| DK (1) | DK3849976T3 (enExample) |
| EA (1) | EA202190717A1 (enExample) |
| ES (1) | ES2935705T3 (enExample) |
| FI (1) | FI3849976T3 (enExample) |
| HR (1) | HRP20230067T1 (enExample) |
| HU (1) | HUE060943T2 (enExample) |
| IL (1) | IL281335B2 (enExample) |
| LT (1) | LT3849976T (enExample) |
| MX (1) | MX2021003010A (enExample) |
| PH (1) | PH12021550299A1 (enExample) |
| PL (1) | PL3849976T3 (enExample) |
| PT (1) | PT3849976T (enExample) |
| SG (1) | SG11202101360VA (enExample) |
| SI (1) | SI3849976T1 (enExample) |
| WO (1) | WO2020053377A1 (enExample) |
| ZA (1) | ZA202100976B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022219046A1 (en) | 2021-04-16 | 2022-10-20 | Saniona A/S | A gaba receptor modulator for use in the treatment of pain |
| WO2025056753A1 (en) * | 2023-09-15 | 2025-03-20 | Saniona A/S | A gaba receptor modulator for treating disorders associated with sleep spindle deficits |
| WO2025056751A1 (en) * | 2023-09-15 | 2025-03-20 | Saniona A/S | A gaba receptor modulator for use in the treatment of absence seizures |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU675484B2 (en) | 1993-03-24 | 1997-02-06 | Neurosearch A/S | Benzimidazole compounds, their use and preparation |
| GB9702524D0 (en) | 1997-02-07 | 1997-03-26 | Merck Sharp & Dohme | Therapeutic agents |
| GB9813576D0 (en) | 1998-06-24 | 1998-08-19 | Merck Sharp & Dohme | Therapeutic agents |
| ATE284403T1 (de) | 1999-01-27 | 2004-12-15 | Merck Sharp & Dohme | Triazolopyridazinderivate als liganden für gaba- rezeptoren |
| GB9921150D0 (en) * | 1999-09-07 | 1999-11-10 | Merck Sharp & Dohme | Therapeutic agents |
| GB0208394D0 (en) | 2002-04-11 | 2002-05-22 | Merck Sharp & Dohme | Therapeutic agents |
| GB0208392D0 (en) | 2002-04-11 | 2002-05-22 | Merck Sharp & Dohme | Therapeutic compounds |
| GB0212048D0 (en) * | 2002-05-24 | 2002-07-03 | Merck Sharp & Dohme | Therapeutic agents |
| WO2004087690A2 (en) | 2003-04-03 | 2004-10-14 | Neurosearch A/S | Benzimidazole derivatives and their use for modulating the gaba-a receptor complex |
| TWI391381B (zh) | 2006-03-24 | 2013-04-01 | Neurosearch As | 新穎的苯并咪唑衍生物、含有其之醫藥組成物、及其於製造藥物之用途 |
| TW201029986A (en) | 2008-11-14 | 2010-08-16 | Neurosearch As | Novel compounds |
| MX388862B (es) | 2016-01-27 | 2025-03-20 | Univ Zuerich | Uso de moduladores de receptores de gabaa para el tratamiento de picor. |
-
2019
- 2019-09-13 LT LTEPPCT/EP2019/074465T patent/LT3849976T/lt unknown
- 2019-09-13 ES ES19765747T patent/ES2935705T3/es active Active
- 2019-09-13 HR HRP20230067TT patent/HRP20230067T1/hr unknown
- 2019-09-13 PT PT197657471T patent/PT3849976T/pt unknown
- 2019-09-13 SI SI201930443T patent/SI3849976T1/sl unknown
- 2019-09-13 MX MX2021003010A patent/MX2021003010A/es unknown
- 2019-09-13 AU AU2019338236A patent/AU2019338236B2/en active Active
- 2019-09-13 US US17/272,971 patent/US11396510B2/en active Active
- 2019-09-13 WO PCT/EP2019/074465 patent/WO2020053377A1/en not_active Ceased
- 2019-09-13 EA EA202190717A patent/EA202190717A1/ru unknown
- 2019-09-13 SG SG11202101360VA patent/SG11202101360VA/en unknown
- 2019-09-13 IL IL281335A patent/IL281335B2/en unknown
- 2019-09-13 HU HUE19765747A patent/HUE060943T2/hu unknown
- 2019-09-13 BR BR112021004661-5A patent/BR112021004661A2/pt unknown
- 2019-09-13 KR KR1020217006185A patent/KR102712565B1/ko active Active
- 2019-09-13 DK DK19765747.1T patent/DK3849976T3/da active
- 2019-09-13 JP JP2021514324A patent/JP7353663B2/ja active Active
- 2019-09-13 CA CA3110283A patent/CA3110283A1/en active Pending
- 2019-09-13 FI FIEP19765747.1T patent/FI3849976T3/fi active
- 2019-09-13 PL PL19765747.1T patent/PL3849976T3/pl unknown
- 2019-09-13 EP EP19765747.1A patent/EP3849976B1/en active Active
- 2019-09-13 CN CN201980059446.2A patent/CN112714765B/zh active Active
-
2021
- 2021-02-10 PH PH12021550299A patent/PH12021550299A1/en unknown
- 2021-02-12 ZA ZA2021/00976A patent/ZA202100976B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3849976B1 (en) | 2022-10-26 |
| KR102712565B1 (ko) | 2024-10-02 |
| JP7353663B2 (ja) | 2023-10-02 |
| JP2022500445A (ja) | 2022-01-04 |
| BR112021004661A2 (pt) | 2021-06-01 |
| EP3849976A1 (en) | 2021-07-21 |
| EA202190717A1 (ru) | 2021-09-22 |
| LT3849976T (lt) | 2023-02-10 |
| ZA202100976B (en) | 2022-08-31 |
| US20210332042A1 (en) | 2021-10-28 |
| DK3849976T3 (da) | 2023-01-23 |
| SG11202101360VA (en) | 2021-03-30 |
| FI3849976T3 (fi) | 2023-02-19 |
| SI3849976T1 (sl) | 2023-03-31 |
| IL281335B1 (en) | 2024-03-01 |
| HUE060943T2 (hu) | 2023-04-28 |
| AU2019338236A1 (en) | 2021-05-20 |
| IL281335A (en) | 2021-04-29 |
| HRP20230067T1 (hr) | 2023-03-17 |
| US11396510B2 (en) | 2022-07-26 |
| KR20210061338A (ko) | 2021-05-27 |
| PL3849976T3 (pl) | 2023-02-27 |
| ES2935705T3 (es) | 2023-03-09 |
| AU2019338236B2 (en) | 2025-01-09 |
| CN112714765A (zh) | 2021-04-27 |
| PT3849976T (pt) | 2023-01-13 |
| PH12021550299A1 (en) | 2021-10-25 |
| MX2021003010A (es) | 2021-05-27 |
| WO2020053377A1 (en) | 2020-03-19 |
| CA3110283A1 (en) | 2020-03-19 |
| CN112714765B (zh) | 2023-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Koivisto et al. | TRPA1 antagonists for pain relief | |
| CN101589026B (zh) | 治疗脑神经胶质瘤的方法 | |
| CN111655669A (zh) | 治疗包括运动神经元疾病的神经紊乱的组合物和方法 | |
| EA021303B1 (ru) | Способы лечения или профилактики рвоты с помощью агентов, усиливающих секрецию гормона роста | |
| US20150148256A1 (en) | Bioluminescence imaging-based screening assay and inhibitors of abcg2 | |
| US11396510B2 (en) | GABAA receptor ligand | |
| KR102015484B1 (ko) | 순수한 5-ht6 수용체 길항제와 아세틸콜린에스테라제 저해제의 조합물 | |
| JP6629464B2 (ja) | 純粋な５−ｈｔ６受容体アンタゴニスト、アセチルコリンエステラーゼ阻害剤及びｎｍｄａ受容体アンタゴニストの３種類の組合せ | |
| JP2020525480A (ja) | 純粋な５−ｈｔ６受容体アンタゴニストの新たな使用 | |
| HK40057209B (en) | A gabaa receptor ligand | |
| HK40057209A (en) | A gabaa receptor ligand | |
| KR20240012533A (ko) | 자가면역, 동종면역, 염증성 및 미토콘드리아 질환 치료용 조성물 및 이의 용도 | |
| CN103284982A (zh) | 用于治疗癌症转移的方法和组合物 | |
| EA042675B1 (ru) | Лиганд рецептора гамк-а | |
| AU2015363757B2 (en) | Diarylmethylidene piperidine derivatives and their use as delta opioid receptor agonists | |
| DE102013107024A1 (de) | Methoden und Zusammensetzungen zum Behandeln, Modifizieren und Handhaben von Knochenkrebsschmerz | |
| US20240165129A1 (en) | Methods of treating pain and depression | |
| JPH10236963A (ja) | カルシウムチャンネル拮抗剤 | |
| WO2025042610A1 (en) | Pifithrin analogues and methods of treating rett syndrome | |
| JP2023046235A (ja) | 医薬組成物及びｓｔａｔ３のリン酸化阻害剤 | |
| CN103948577A (zh) | 化合物在制备用于治疗、减缓或处理骨癌疼痛的组成物的用途 | |
| US20150322083A1 (en) | (THIENO[2,3-b][1,5]BENZOXAZEPIN-4-YL)PIPERAZIN-1-YL COMPOUNDS AS SELECTIVE 5-HT2A INVERSE AGONISTS | |
| HK40014203A (en) | New uses of a pure 5-ht 6 receptor antagonist |